Paraneoplastic pemphigus

Paraneoplastic pemphigus (PNP) is a life-threatening autoimmune mucocutaneous blistering disease associated with malignancy, particularly lymphoproliferative neoplasms. Clinically, it is characterized by severe and intractable mucositis and polymorphous cutaneous eruptions, ranging from blisters to...

Full description

Bibliographic Details
Main Authors: Sang Eun Lee, Soo-Chan Kim
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2010-03-01
Series:Dermatologica Sinica
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1027811710600018
_version_ 1811213450108469248
author Sang Eun Lee
Soo-Chan Kim
author_facet Sang Eun Lee
Soo-Chan Kim
author_sort Sang Eun Lee
collection DOAJ
description Paraneoplastic pemphigus (PNP) is a life-threatening autoimmune mucocutaneous blistering disease associated with malignancy, particularly lymphoproliferative neoplasms. Clinically, it is characterized by severe and intractable mucositis and polymorphous cutaneous eruptions, ranging from blisters to lichenoid lesions. The histologic features are also diverse according to the morphology of the clinical lesions, ranging from suprabasal acantholysis to interface changes with necrotic keratinocytes. PNP is characterized by the production of autoantibodies against the plakin family proteins as well as the desmoglein 1 and 3, which are target antigens of ordinary pemphigus. Thus, indirect immunofluorescence on substrates other than skin is useful in the diagnosis of PNP. The presence of anti-desmoglein antibodies have been demonstrated by enzyme-linked immunosorbent assay. The gold standard for the diagnosis of PNP however, is the detection of the characteristic circulating autoantibodies against 210-kDa envoplakin and 190-kDa periplakin by immunoblotting or immunoprecipitation. It is now accepted that both humoral and cellular immunities are involved in the pathogenesis of PNP. Anti-desmoglein 3 antibodies are known to play a pathogenic role in the initiation of acantholytic blister formation. Autoreactive CD8 + cytotoxic T cells induced by antitumor immune response are also involved in the development of mucocutaneous manifestations and bronchiolotis obliterans. The prognosis of PNP depends on the nature of the underlying neoplasm, with high mortality rate due to sepsis or multi-organ failure, particularly bronchiolitis obliterans. Although the combined use of immunosup-pressive agents and rituximab has been administered in treating PNP, to date, there are no consistently effective treatments for PNP.
first_indexed 2024-04-12T05:45:53Z
format Article
id doaj.art-f4cfe260f6b946ebbac6a4d02209e6c2
institution Directory Open Access Journal
issn 1027-8117
language English
last_indexed 2024-04-12T05:45:53Z
publishDate 2010-03-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Dermatologica Sinica
spelling doaj.art-f4cfe260f6b946ebbac6a4d02209e6c22022-12-22T03:45:27ZengWolters Kluwer Medknow PublicationsDermatologica Sinica1027-81172010-03-0128111410.1016/S1027-8117(10)60001-8Paraneoplastic pemphigusSang Eun LeeSoo-Chan KimParaneoplastic pemphigus (PNP) is a life-threatening autoimmune mucocutaneous blistering disease associated with malignancy, particularly lymphoproliferative neoplasms. Clinically, it is characterized by severe and intractable mucositis and polymorphous cutaneous eruptions, ranging from blisters to lichenoid lesions. The histologic features are also diverse according to the morphology of the clinical lesions, ranging from suprabasal acantholysis to interface changes with necrotic keratinocytes. PNP is characterized by the production of autoantibodies against the plakin family proteins as well as the desmoglein 1 and 3, which are target antigens of ordinary pemphigus. Thus, indirect immunofluorescence on substrates other than skin is useful in the diagnosis of PNP. The presence of anti-desmoglein antibodies have been demonstrated by enzyme-linked immunosorbent assay. The gold standard for the diagnosis of PNP however, is the detection of the characteristic circulating autoantibodies against 210-kDa envoplakin and 190-kDa periplakin by immunoblotting or immunoprecipitation. It is now accepted that both humoral and cellular immunities are involved in the pathogenesis of PNP. Anti-desmoglein 3 antibodies are known to play a pathogenic role in the initiation of acantholytic blister formation. Autoreactive CD8 + cytotoxic T cells induced by antitumor immune response are also involved in the development of mucocutaneous manifestations and bronchiolotis obliterans. The prognosis of PNP depends on the nature of the underlying neoplasm, with high mortality rate due to sepsis or multi-organ failure, particularly bronchiolitis obliterans. Although the combined use of immunosup-pressive agents and rituximab has been administered in treating PNP, to date, there are no consistently effective treatments for PNP.http://www.sciencedirect.com/science/article/pii/S1027811710600018Autoantibodies to plakin and desmogleinCellular immunityHumoral immunityParaneoplastic pemphigus
spellingShingle Sang Eun Lee
Soo-Chan Kim
Paraneoplastic pemphigus
Dermatologica Sinica
Autoantibodies to plakin and desmoglein
Cellular immunity
Humoral immunity
Paraneoplastic pemphigus
title Paraneoplastic pemphigus
title_full Paraneoplastic pemphigus
title_fullStr Paraneoplastic pemphigus
title_full_unstemmed Paraneoplastic pemphigus
title_short Paraneoplastic pemphigus
title_sort paraneoplastic pemphigus
topic Autoantibodies to plakin and desmoglein
Cellular immunity
Humoral immunity
Paraneoplastic pemphigus
url http://www.sciencedirect.com/science/article/pii/S1027811710600018
work_keys_str_mv AT sangeunlee paraneoplasticpemphigus
AT soochankim paraneoplasticpemphigus